Get All Access for FREE

Market News & Research,
Fundamental Data,
Live Transcripts & Audio,
AlphaGraphics,

and a whole lot more…

{{::item.ticker}} • {{::item.company_name}} No Results

Get All Access for FREE

Market News & Research,
Fundamental Data,
Live Transcripts & Audio,
AlphaGraphics,

and a whole lot more…

News & Research
Portfolio
Discover
Groups
$PFE {{ '2015-06-24T07:28:32+0000' | timeago}} • SEC

$PFE 1Q15 10-Q: On Feb. 5, 2015, PFE have entered into a definitive merger agreement under which it has agreed to acquire Hospira, Inc., a leading provider of injectable drugs and infusion technologies and a global leader in biosimilars, for $90 per share in cash, for a total enterprise value of approx. $17Bil and is expected to close in 1H15.

$PFE {{ '2018-05-11T13:23:54+0000' | timeago}} • Infographic

$PFE Pfizer Inc. Earnings AlphaGraphic: Q1 2018 Highlights

$PFE {{ '2018-01-30T17:15:55+0000' | timeago}} • Announcement

$PFE anticipates its fiscal 2018 revenue will be in the range of $53.5Bil to $55.5Bil, with the midpoint implying a 4% annual growth. Non-GAAP earnings per share are forecasted between $2.90 and $3.00. This year, the company expects repatriation tax liability of about $15Bil, payable to the US Treasury.

$PFE {{ '2018-01-30T17:10:02+0000' | timeago}} • Announcement

Pharmaceutical giant $PFE said its profit surged in fourth quarter, owing to a huge tax gain. Earnings jumped to $2.02 per share from $0.13 per share last year. Revenues remained broadly unchanged at $13.7Bil, with a rise in Innovative Health revenue offsetting a decline in Essential Health. Non-GAAP earnings were $0.61 per share, up 32% from 4Q16.

$PFE {{ '2018-01-30T13:34:11+0000' | timeago}} • Infographic

$PFE Pfizer Inc. Earnings AlphaGraphic: Q4 2017 Highlights

$PFE {{ '2018-01-04T13:11:11+0000' | timeago}} • Announcement

Arvinas LLC collaborates with $PFE for the discovery and development of drug candidates using Arvinas' PROTAC Platform, a novel technology used to create small molecule therapeutics aimed at degrading disease-causing cellular proteins. Arvinas may receive up to $830MM in upfront and potential development and commercialization milestone payments.

$PFE {{ '2017-12-26T12:25:28+0000' | timeago}} • Announcement

$PFE and $MRK announced that the US FDA has approved STEGLATRO (ertugliflozin) tablets, an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, and the fixed-dose combination STEGLUJAN (ertugliflozin and sitagliptin) tablets for adults with type 2 diabetes.

$MRK {{ '2017-12-22T16:34:34+0000' | timeago}} • Announcement

$MRK and $PFE announced that the FDA approved STEGLATROTM (ertugliflozin) tablets, an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, and the fixed-dose combination STEGLUJAN (ertugliflozin and sitagliptin) tablets.

$PFE {{ '2017-12-21T21:14:41+0000' | timeago}} • Announcement

$PFE announced that the US FDA has granted Breakthrough Therapy Designation for avelumab in combination with INLYTA for treatment-naive patients with advanced renal cell carcinoma (RCC). This is the second Breakthrough Therapy Designation granted to avelumab.

$PFE {{ '2017-12-20T12:23:04+0000' | timeago}} • Announcement

The US FDA has approved $PFE's supplemental New Drug Application to expand the indication for BOSULIF  to include adult patients with newly-diagnosed chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph CML).

$PFE {{ '2017-12-18T19:31:58+0000' | timeago}} • Announcement

The BoD of $PFE has increased the quarterly dividend by 6% to $0.34 per share. The first quarter 2018 cash dividend will be payable on March 1, 2018, to shareholders of record on Feb. 2, 2018. The board also authorized a new $10Bil share repurchase program, in addition to the $6.4Bil remaining under the current authorization.

$LLY {{ '2017-12-11T17:36:13+0000' | timeago}} • Announcement

FDA accepts to review $LLY's Galcanezumab, an injectionable drug for the treatment of migraine. Rivals $NVS and $AMGN already filed their migraine drug with FDA in July 2017, while $TEVA is also expected to join the race. Lilly's pain portfolio also includes Tanezumab, developed in partnership with $PFE, for the treatment of osteoarthritis.

$JCI {{ '2017-12-11T16:43:09+0000' | timeago}} • Announcement

$JCI's BoD appointed John Young to serve as a director. Young is currently group president of $PFE Essential Health. Effective Jan. 1, 2018, he will become group president of Pfizer Innovative Health, which comprises six business groups focused on improving health through innovative products covering every stage of life.

$PFE {{ '2017-12-01T11:52:44+0000' | timeago}} • Announcement

$PFE enters into agreement with Basilea Pharmaceutica Ltd to develop and commercialize CRESEMBA in China and Asia Pacific region. CRESEMBA is a novel antifungal medicine for the treatment of adult patients with diagnosed invasive aspergillosis and mucormycosis.

$PFE {{ '2017-11-17T11:53:03+0000' | timeago}} • Announcement

The US FDA has approved a new use for $PFE’s cancer drug SUTENT. The drug was approved as an adjuvant in renal cell carcinoma (RCC) following nephrectomy (surgical removal of the cancerous kidney).

$PFE {{ '2017-11-13T15:41:23+0000' | timeago}} • Announcement

$PFE has named Albert Bourla as COO effective Jan. 1, 2018. Also effective Jan. 1, John Young, Group President, Pfizer Essential Health will become Group President, Pfizer Innovative Health. Angela Hwang, Global President and General Manager for Pfizer Inflammation & Immunology will succeed John Young as Group President, Pfizer Essential Health.

$PFE {{ '2017-11-07T13:59:46+0000' | timeago}} • Webcast

$PFE welcomes the potential changes in drug distribution models. With $AMZN considering an entry into the pharmacy space, CEO Ian Read on the company's 3Q17 earnings call said, “Any system of distribution that can cut costs and get a wide availability of products to patients is something that the whole industry would be interested.”

$PFE {{ '2017-11-07T13:49:05+0000' | timeago}} • Webcast

$PFE’s Innovative Health business had strong 3Q17, driven by continued growth of key brands, including Ibrance and Eliquis globally and Xtandi, Lyrica, Xeljanz and Chantix in the US. On the other hand, Essential Health business saw revenue declining in the quarter, but had strong operational growth in emerging markets and in biosimilars portfolio.

$PFE {{ '2017-10-31T14:38:09+0000' | timeago}} • Announcement

$PFE's Innovative Health division, which sells newer, patent-protected medicines, posted an 11% increase in revenue for 3Q17, while Essential Health, that sells older drugs, fell 12%. The company lifted its FY17 EPS forecast to $2.58-2.62 from the previous range of $2.54-2.60, with revenue ranging between $52.4Bil and $53.1Bil.

$PFE {{ '2017-10-31T14:24:43+0000' | timeago}} • Announcement

With slightly higher sales and lower one-time charges, $PFE saw its profit double for 3Q17 to $2.8Bil, or $0.47 per share, from $1.35Bil, or $0.22 per share, a year ago. Revenue edged up nearly 1% to $13.2Bil, driven by higher sales from most of its key new drugs, including cancer medicine Ibrance that grew 60% YoY.

$PFE {{ '2017-10-31T12:07:05+0000' | timeago}} • Infographic

$PFE Pfizer Inc. Earnings AlphaGraphic: Q3 2017 Highlights

Recent Transcripts
NEPT | Earnings
August 15th 2018, 12:00pm
ARRY | Earnings
August 14th 2018, 1:00pm
NKTR | Earnings
August 8th 2018, 9:00pm
OSUR | Earnings
August 8th 2018, 9:00pm
AlphaGraphics you may like
Related Feed
Recent Transcripts
NEPT | Earnings
August 15th 2018, 12:00pm
ARRY | Earnings
August 14th 2018, 1:00pm
NKTR | Earnings
August 8th 2018, 9:00pm
OSUR | Earnings
August 8th 2018, 9:00pm
AlphaGraphics you may like